Biohaven Ltd. Deferred Tax Assets, in Process Research and Development
Biohaven Ltd. (BHVN) had Deferred Tax Assets, in Process Research and Development of $2.37 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $2.37M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $5.89M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $887.00K.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $142.27M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $2.37M 10-K · filed 2026-03-02 |
| 2024-12-31 | $5.89M 10-K · filed 2026-03-02 |
| 2023-12-31 | $887.00K 10-K · filed 2025-03-03 |
| 2022-12-31 | $142.27M 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |